Description: Physiomics Plc is engaged in the provision of outsourced systems and computational biology services to pharmaceutical companies. The Company is focused on the development of Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials; Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates in the drug discovery process, and Drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical regimens and their effects. Its services include Target Validation, Mechanism of Action Studies, Lead Selection, Clinical Pharmacokinetic/Pharmacodynamics (PK/PD), EASYAP/Cardiac Toxicity Service, Virtual Tumour Preclinical and Virtual Tumour Clinical. It offers a services and technology for predicting cardiac toxicity. It also focuses on offering offer Model Based Drug Development (MBDD) services, which include Population PKPD analysis of clinical data and Back-translational analysis.
Home Page: www.physiomics.co.uk
PYC Technical Analysis
The Magdalen Centre
Oxford,
OX4 4GA
United Kingdom
Phone:
44 18 6578 4980
Officers
| Name | Title |
|---|---|
| Dr. James Simon Millen | CEO & Exec. Chairman |
| Dr. Christophe D. Chassagnole Ph.D. | COO & Exec. Director |
| Prof. David Fell | Co-Founder & Member of Scientific Advisory Board |
| Mr. Anthony Louis Clayden ACA, BSc (Hons), MSI | Head of Fin. & Company Sec. |
| Ms. Charmaine Fraser | Admin. Mang. |
| Ms. Hayley Close | Head of Bus. Devel. |
| Dr. Mark Middleton M.D., Ph.D. | Consultant & Member of Scientific Advisory Board |
| Dr. Robert Jackson Ph.D. | Consultant & Member of Scientific Advisory Board |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7984 |
| Price-to-Sales TTM: | 2.9204 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 8 |